Special Issue "New Studies on the Synthesis of Biologically Active Products"
Deadline for manuscript submissions: 30 September 2019
Prof. Dr. Vincenzo Piccialli
Universita degli Studi di Napoli Federico II, Department of Chemical Sciences, Naples, Italy
Website | E-Mail
Interests: organic synthesis; new synthetic methods; medicinal chemistry; structure–activity relationship (SAR); biological activity; oxidation methods; catalytic processes; marine natural substances
The search for novel biologically-active substances is a major goal of medicinal chemistry, as highlighted by the emergency represented by the need for, as examples, new antibacterial or antiviral substances. Nature is very often the source of new lead compounds that constitute the starting point for the elaboration of new drugs. However, nature is sometimes miserly and substances possessing important biological activities are often obtained only in minute amounts from the natural source. In this context, synthetic organic chemists play a central role as witnessed by their incessant efforts to increase the biological effectiveness of known or new drugs through suitable structural modifications of the basic molecular architecture or to devise efficient routes to access such products in the required quantities. The construction of structurally complex molecules can be the bench test to verify the effectiveness of emerging synthetic methodologies or to discover new processes. Although this can imply a certain level of risk, synthetic plans, including new processes, intrinsically possess an added value and often contribute to the advancement of the science of organic synthesis. It is also worth highlighting that the work of synthetic chemists is increasingly supported by the close collaboration with biologists.
The purpose of this Special Issue is to gather original articles and reviews dealing with the synthesis of biologically active substances. According to the premise, synthetic studies accompanied by biological assays, or reporting new evidence on the use of known or emerging synthetic methods, would be very welcome.
Prof. Dr. Vincenzo Piccialli
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Organic synthesis
- New synthetic methods
- Medicinal chemistry
- Structure–activity relationship (SAR)
- Biological activity
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Author: Maria Marinescu
Abstract: Novel benzimidazole Mannich bases were synthesized from 2-hydroxyethyl- benzimidazole, amines and formaldehyde by a one-pot synthesis. The structures of the new compounds are conﬁrmed by 1H, 13C NMR, FTIR, MS spectra and elemental analysis. All benzimidazole compounds were screened by qualitative and quantitative methods for their in vitro antibacterial activity against 4 bacterial strains. The best minimum inhibitory concentration (MIC) is observed for (S)-1-(1-((4-methylpiperazin-1-yl)methyl)-1H-benzo[d] imidazol-2-yl)ethanol on all tested strains. DFT studies were accomplished in order to optimize all Mannich bases using GAMESS 2012 software and HOMO-LUMO analysis allowed the calculation of electronic and structural parameters. Antimicrobial activity of the Manncih benzimidazoles is correlated with theirs electronic and geometric parameters, and also with Mullikan atomic charges on the atoms.